US Stock MarketDetailed Quotes
NEUP Neuphoria Therapeutics
- 6.630
- +3.593+118.29%
Close Dec 24 13:00 ET
- 5.020
- -1.610-24.28%
Post 16:59 ET
10.79MMarket Cap-0.43P/E (TTM)
10.500High3.750Low1.18MVolume10.200Open3.037Pre Close8.26MTurnover84.30%Turnover RatioLossP/E (Static)1.63MShares18.00052wk High0.63P/B9.24MFloat Cap2.12452wk Low--Dividend TTM1.39MShs Float264.000Historical High--Div YieldTTM222.24%Amplitude2.112Historical Low7.023Avg Price1Lot Size
About Neuphoria Therapeutics Company
Bionomics Ltd. is a clinical stage biopharmaceutical company, which develops novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Its lead product candidate is BNC210. The company was founded in 1996 and is headquartered in Eastwood, Australia.
Company Profile
SymbolNEUP
Company NameNeuphoria Therapeutics
Founded1996
CEODr. Spyros Papapetropoulos, PhD
MarketNASDAQ
Employees24
Fiscal Year Ends06-30
Address200 Greenhill Road
CityEastwood
ProvinceSouth Australia (SA)
CountryAustralia
Zip Code5063
Phone61-8-8150-7400
Websitehttp://www.bionomics.com.au
Company Executives
- Name
- Position
- Salary
- Dr. Spyros Papapetropoulos, PhD
- Director, President and Chief Executive Officer
- 919.77K
- Timothy M. Cunningham
- Chief Financial Officer
- --
- Adrian Hinton
- Financial Controller and Principal Accounting Officer
- 299.55K
- Liz Doolin
- Vice President, Clinical Development
- 357.03K
- Alan Fisher
- Chairman of the Board
- 87.00K
- David Wilson
- Independent Director
- 87.00K
- Peter Miles Davies
- Independent Director
- 77.00K
- Dr. Jane Ryan, PhD
- Independent Director
- 86.72K
Heat List
US
Overall
Symbol
Price
% Chg
No Data
